Sacral neuromodulation vs Botox for overactive bladder
If behavioral changes and bladder medications haven’t brought your overactive bladder under control, there are two well-established next steps: sacral neuromodulation (SNM, often called InterStim) and bladder Botox (onabotulinumtoxinA). Both are considered third-line therapies for urgency and urgency incontinence, meaning they come after first-line behavioral therapy and pelvic floor work and after a trial of medication. Guidelines don’t require you to march through every option in a fixed order, though. The choice between them is yours to make with your physician, based on your symptoms, your goals, and what fits your life.
Both work well. In the largest head-to-head trial, the two came out about equal for reducing urgency-incontinence episodes by the one- to two-year mark. Where they really differ is in how they’re delivered and the trade-offs that come with each.
How sacral neuromodulation works
SNM uses a small implanted device, similar to a pacemaker, to send mild electrical pulses to the sacral nerves that help control the bladder. Instead of acting on the bladder muscle directly, it adjusts the nerve signals between the bladder and the brain.
One feature sets it apart: you try before you commit. During a test phase of roughly one to two weeks, a thin temporary wire delivers the therapy so you can see how much your symptoms improve. Only if the test goes well do you move to the permanent implant.
A few details that tend to matter:
- The test phase is the single best predictor of whether the implant will help you.
- The device runs continuously and can be adjusted; many women need their settings reprogrammed at some point, usually a quick office visit.
- Battery life is in the range of 10-15 years.
- The device can be turned off or removed.
- It can also improve fecal incontinence, so it’s worth considering if you have both.
- Most current devices are labeled for full-body MRI under specific conditions, but let any imaging team know you have an implant.
How bladder Botox works
Botox is injected into the bladder muscle through a cystoscope during a short office procedure with local anesthetic. It calms the involuntary bladder contractions that drive urgency and leakage, and the effect builds over the first one to two weeks.
What to expect:
- Nothing is implanted, and there’s no surgery.
- The effect lasts about six to nine months, so you return for repeat injections when symptoms come back.
- The main trade-off is bladder emptying. Some women don’t empty completely afterward, and a portion of them need to use a catheter for a while until the effect settles or wears off. We check your emptying after treatment.
- Urinary tract infections are more common after Botox than after SNM. If you’re already prone to them, that’s worth factoring in.
- If it doesn’t suit you, you simply don’t repeat it.
How they compare
| Sacral neuromodulation | Botox injections | |
|---|---|---|
| What it does | Adjusts the nerve signals controlling the bladder | Calms overactive bladder-muscle contractions |
| Procedure | Test phase with a temporary wire, then an implant if it works | Office injection through a cystoscope, repeated over time |
| Onset | Judged during the test phase | About 1 to 2 weeks |
| How long it lasts | Continuous; batteries last about 10 to 15 years | About 6 to 9 months per injection |
| Adjustable | Yes, settings can be reprogrammed | No, fixed until the effect fades |
| Main trade-offs | Surgical risks, lead migration, occasional device revision | Incomplete emptying, sometimes temporary self-catheterization, higher UTI rate |
| Reversibility | Device can be turned off or removed | Effect wears off on its own |
| Upkeep | Occasional reprogramming; battery replacement years later | Repeat injections roughly every 6 to 12 months |
Cost is also part of the picture. Botox carries a much lower upfront cost, while SNM involves a more expensive device and implant procedure, even though long-term symptom control is similar. Insurance coverage varies, and some plans ask you to have tried medications first before they’ll cover either option. That’s an insurance rule, not a medical requirement. We’ll help you understand what your plan involves.
Dr. Stewart’s perspective
Both of these are good treatments, and the research backs that up. Over a couple of years, they control symptoms about equally well. So the decision usually comes down to how you’d rather live with the treatment.
Some women like that SNM runs in the background once it’s in place, and they value the test phase: you get to feel the therapy before deciding on the implant. Others prefer Botox because nothing stays in the body and they don’t mind coming back for an injection now and then. Neither answer is wrong. The honest trade-offs are real on both sides. Botox can make emptying harder for a while and carries a higher UTI risk, and SNM is a surgical implant that occasionally needs adjusting or revision. We’ll talk all of that through.
If you’d rather avoid both for now, tibial neuromodulation is another option for urgency symptoms. It’s the least invasive of the neuromodulation approaches, done in the office, though it needs repeat sessions to keep working.
Who tends to do well with each
Sacral neuromodulation may suit you if you:
- want continuous therapy you don’t have to think about day to day
- would rather not return for periodic procedures
- like being able to fine-tune the settings
- also have fecal incontinence, since SNM can help both
- prefer the reassurance of a test phase before committing
Botox may suit you if you:
- would rather not have an implanted device
- don’t mind periodic office visits
- want to avoid surgery
- want to start with something that reverses on its own
- aren’t especially prone to urinary tract infections
Making your decision
The best treatment is the one that fits your symptoms and your priorities. Dr. Stewart will walk you through both options and answer your questions so you can choose with confidence. And if your first choice doesn’t pan out, the other one is still there.
References
- Amundsen CL, Richter HE, Menefee SA, et al. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial. JAMA. 2016. doi:10.1001/jama.2016.14617
- Amundsen CL, Komesu YM, Chermansky C, et al. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. European Urology. 2018. doi:10.1016/j.eururo.2018.02.011
- Harvie HS, Amundsen CL, Neuwahl SJ, et al. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial. Journal of Urology. 2020. doi:10.1097/JU.0000000000000656
- Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. The Journal of Urology. 2019. doi:10.1097/JU.0000000000000309
- ACOG Committee on Practice Bulletins—Gynecology, American Urogynecologic Society, Kenton KS, et al. Urinary Incontinence in Women (ACOG Practice Bulletin No. 155). Obstetrics & Gynecology. 2015. doi:10.1097/AOG.0000000000001148
- Goldman HB, Lloyd JC, Noblett KL, et al. International continence society best practice statement for use of sacral neuromodulation. Neurourology and Urodynamics. 2018. doi:10.1002/nau.23596
- Komesu YM, Amundsen CL, Richter HE, et al. Refractory Urgency Urinary Incontinence Treatment in Women: Impact of Age on Outcomes and Complications. American Journal of Obstetrics and Gynecology. 2018. doi:10.1016/j.ajog.2017.10.006
- White N, Iglesia CB. Overactive Bladder. Obstetrics and Gynecology Clinics of North America. 2016. doi:10.1016/j.ogc.2015.10.002
- Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized Trial of Percutaneous Tibial Nerve Stimulation Versus Sham Efficacy in the Treatment of Overactive Bladder Syndrome: Results From the SUmiT Trial. The Journal of Urology. 2010. doi:10.1016/j.juro.2009.12.036
- Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous Tibial Nerve Stimulation for the Long-Term Treatment of Overactive Bladder: 3-Year Results of the STEP Study. The Journal of Urology. 2013. doi:10.1016/j.juro.2012.11.175